DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 018705/S-019

SUPPLEMENT APPROVAL

G. Pohl Boskamp GmbH & Co. KG
Kieler Strasse 11
Hohenlockstedt Germany, EU 25551

Dear Applicant:

Please refer to your Supplemental New Drug Application (sNDA) dated May 30, 2014, received June 2, 2014, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Nitrolingual Pumpspray 400 mcg per spray dose.

This "Prior Approval" supplemental new drug application provides for revisions to the labeling to comply with the requirements of 21 CFR 201.56(a) and (d) and 201.57. Editorial and organizational changes have been made throughout the labeling. Content changes have been made in Sections 1, 2, 4, 5, 6, 7, 8, 10, 12, 13, 14 and 17 as well as the Instructions for Use.

APPROVAL & LABELING

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Michael Monteleone, Regulatory Project Manager, at (301) 796-1952.

Sincerely,

{See appended electronic signature page}

Norman Stockbridge, MD, PhD
Director
Division of Cardiovascular and Renal Drugs
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Cc: Arbor Pharmaceuticals, LLC
Attention: Allison Lowry
Director Regulatory Affairs
6 Concourse Parkway
Suite 1800
Atlanta, GA 30328

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

NORMAN L STOCKBRIDGE
01/23/2015